<DOC>
	<DOCNO>NCT00975286</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) , comparison placebo , add-on treatment insulin glargine metformin without thiazolidinediones ( TZDs ) , period 24 week treatment . The primary objective ass effect lixisenatide comparison placebo , add insulin glargine metformin , glycemic control term glycosylated hemoglobin ( HbA1c ) reduction ( absolute change ) Week 24 . The secondary objective assess effect lixisenatide percentage patient reach HbA1c le ( &lt; ) 7 percent ( % ) less equal ( &lt; = ) 6.5 % , plasma glucose ( fast , postprandial standardized meal challenge test , 7-point self monitor profile ) , body weight , insulin glargine dos , evaluate safety tolerability ( include anti-lixisenatide antibody assessment ) , assess impact treatment satisfaction use Diabetes Treatment Satisfaction Questionnaire ( state ) ( DTSQs ) participate country validate .</brief_summary>
	<brief_title>24-week Treatment With Lixisenatide Type 2 Diabetes Insufficiently Controlled With Metformin Insulin Glargine</brief_title>
	<detailed_description>The study comprise 3 period : - An 14-week screening period , include 2-week screen phase 12-week run-in phase introduction titration insulin glargine top metformin +/-TZDs . - At end run-in phase , patient whose HbA1c ( centralize assay ) great equal ( &gt; = ) 7 % less equal ( &lt; = ) 9 % whose mean fast self-monitored plasma glucose ( SMPG ) calculate self measurement 7 day prior Visit 12 ( Week -1 ) &lt; =140 milligram per deciliter ( mg/dL ) ( 7.8 millimole per liter [ mmol/L ] ) , would enter 24-week double-blind randomized treatment period compare lixisenatide placebo ( top insulin glargine + metformin +/- TZDs ) . - A 3-day safety follow period . Maximum duration 39 week +/- 7 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus , diagnose least 1 year screen visit , insufficiently control insulin glargine metformin Exclusion criterion : HbA1c &lt; 7 % great ( &gt; ) 10 % screen At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential effective contraceptive method Type 1 diabetes mellitus Metformin stable dose least 1.5 gram per day least 3 month prior screen visit Use oral injectable antidiabetic hypoglycemic agent metformin , sulfonylurea ( SU ) TZDs ( example , alpha glucosidase inhibitor , glucagon like peptide1 [ GLP1 ] receptor agonist , dipeptidyl peptidaseIV [ DPPIV ] inhibitor , insulin etc . ) within 3 month prior time screening , use weight loss drug stable dose least 3 month prior screen visit History hypoglycemia unawareness Body Mass Index ( BMI ) less equal ( &lt; = ) 20 kilogram per square meter ( kg/m^2 ) History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease , personal family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( example , multiple endocrine neoplasia syndrome ) History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia , blood plasma product transfusion within 3 month prior time screen Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization Known history drug alcohol abuse within 6 month prior time screen Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram vital sign time screen judgment Investigator sub investigator precludes safe completion study constrain efficacy assessment active malignant tumor major systemic disease , presence clinically significant diabetic retinopathy presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest systolic diastolic blood pressure &gt; 180 millimeter mercury ( mmHg ) &gt; 110 mmHg , respectively Laboratory finding time screening : amylase and/or lipase , alanine aminotransferase &gt; 3 time upper limit normal ( ULN ) laboratory range ; total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100 000/mm^3 ; positive test Hepatitis B surface antigen and/or Hepatitis C antibody , positive serum pregnancy test female childbearing potential ; calcitonin &gt; =20 picogram per milliliter ( pg/mL ) ( 5.9 picomole per milliliter [ pmol/L ] ) Patients consider Investigator sub investigator inappropriate study reason ( example , impossibility meet specific protocol requirement , schedule visit , able selfinjections , likelihood require treatment screen phase treatment phase drug permit clinical study protocol , patient investigator sub investigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol etc . ) Use systemic glucocorticoid ( exclude topical application inhale form ) one week within 3 month prior time screen Use investigational drug within 3 month prior screen Renal impairment define serum creatinine &gt; 1.4 mg/dL woman &gt; 1.5 mg/dL men History hypersensitivity insulin glargine excipients Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include ( limited ) : gastroparesis , unstable ( , worsen ) control ( , prolong nausea vomit ) gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Any previous treatment lixisenatide ( example , participation previous study lixisenatide ) Allergic reaction GLP1 receptor agonist past ( example , exenatide , liraglutide ) metacresol Additional exclusion criterion end runin phase randomization : informed consent withdrawal ( patient willing continue fail return ) , mean fast SMPG calculate selfmeasurements 7 day prior Visit 12 ( Week 1 ) &gt; 140 mg/dL ( 7.8 mmol/L ) HbA1c measure Visit 12 ( Week 1 ) &lt; 7 % &gt; 9 % , amylase and/or lipase &gt; 3 time ULN Visit 12 ( Week 1 ) , patient fast plasma glucose ( FPG ) threshold value describe rescue ( , FPG &gt; 240 mg/dL [ 13.3 mmol/L ] ) , patient adverse event , , judgment Investigator preclude inclusion doubleblind randomized treatment phase , lack compliance protocol insulin glargine treatment runin phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>